Content on this page requires a newer version of Adobe Flash Player.
The winner by a mile. When I compiled this list of drug-stock losers, I excluded pink-sheet and bulletin-board issues, but Radient was granted an exemption since the stock sank to the OTC in June.
In 2011, who could forget Radient's business deals with a
dead Indian prime minister
pseudo-partnership with the Mayo Clinic
Then there was
Radient's massive loan default
, the reluctant disclosure that its
India joint venture was a bust
delisting from Amex
The stock: It's not possible to lose more than 100% but Radient came close with the shares plunging 99.6% in 2011.
>>To see these stocks in action, visit the
5 Biggest Drug-Stock Losers of 2011
portfolio on Stockpickr.
--Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here:
>To follow the writer on Twitter, go to
>To submit a news tip, send an email to:
and become a fan on